Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20591996 | 0.87 | SMN1; SMN2 (0.45) | MEN1KMT2A | |
| SCHEMBL4164534 | 0.86 | MAPT (0.34) | KMT2AMAPTHSD17B10 | |
| SCHEMBL17735975 | 0.85 | — | — | |
| SCHEMBL29478056 | 0.84 | — | — | |
| SCHEMBL8003191 | 0.81 | KMT2A (0.41) | MEN1KMT2AMAPTHSD17B10 | |
| SCHEMBL4953772 | 0.77 | KMT2A (0.44) | MEN1KMT2AMAPTHSD17B10 | |
| SCHEMBL17337909 | 0.77 | KMT2A (0.48) | MEN1KMT2ACYP1A2MAPTHSD17B10 | |
| SCHEMBL24725230 | 0.76 | ALOX5 (0.38) | CYP1A2CYP2D6MAPTCYP2C9CYP2C19 | |
| SCHEMBL31225892 | 0.76 | TSHR (0.41) | — | |
| SCHEMBL21049231 | 0.75 | KMT2A (0.43) | MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680222-A1 | N-BETA-HYDROXYBUTYRYL-AMINO ACIDS AND RELATED COMPOSITIONS AND METHODS | The Board of Trustees of the Leland Stanford Junior University (US) | 2026-01-21 | — | — | EP | disclosed |
| WO-2024192165-A1 | N-BETA-HYDROXYBUTYRYL-AMINO ACIDS AND RELATED COMPOSITIONS AND METHODS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-09-19 | — | — | WO | disclosed |
| US-20210284668-A1 | GOLD (I)-PHOSPHINE 1,2,3-TRIAZOLE DERIVATIVES WITH ANTIBIOTIC PROPERTIES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-09-16 | — | — | US | disclosed |
| US-20210255193-A1 | LYSINE REACTIVE PROBES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2021-08-19 | — | — | US | disclosed |
| US-20210255193-A1 | LYSINE REACTIVE PROBES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE | 2021-08-19 | — | — | US | disclosed |
| EP-3642630-A1 | LYSINE REACTIVE PROBES AND USES THEREOF | The Scripps Research Institute (US) | 2020-04-29 | — | — | EP | disclosed |
| WO-2019243273-A1 | GOLD (I)-PHOSPHINE 1,2,3-TRIAZOLE DERIVATIVES WITH ANTIOBIOTIC PROPERTIES | UNIVERSITÉ DE STRASBOURG (FR) | 2019-12-26 | — | — | WO | disclosed |
| WO-2018237334-A1 | LYSINE REACTIVE PROBES AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-12-27 | — | — | WO | disclosed |
| US-20180372751-A1 | LYSINE REACTIVE PROBES AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284668-A1 | GOLD (I)-PHOSPHINE 1,2,3-TRIAZOLE DERIVATIVES WITH ANTIBIOTIC PROPERTIES | PADI3, PADI1, PADI4 | MEN1 969/4885KMT2A 2645/4885CYP1A2 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.